Australian Public Assessment Report for Rifaximin

A secondary issue was the apparent hepatotoxicity reported in earlier non-GLP repeat dose toxicity studies in rats and dogs, not reproduced at higher doses in the current GLP studies. These concerns have prompted the FDA to require the postmarketing conduct of a chronic oral nonclinical toxicology study, with achieved AUC exposures comparable ... ................
................